Ironwood Pharmaceuticals Stock Forecast for 2023 - 2025 - 2030

Updated on 02/05/2023

Stock Rating
14
Price Target
$12.50
Consensus
Neutral
Upside
9.65%
Analysts
1
Stock Rating
14
Upside
9.65%
Analysts
1
Price Target
$12.50

Ironwood Pharmaceuticals Stock Forecast and Price Target

The average price target for Ironwood Pharmaceuticals's stock lately set by several renowned analysts is $12.50, which would result in a potential upside of approximately 9.65% if it reaches this mark by December 31, 2023. This estimation is based on a high estimate of $16.00 and a low estimate of $9.00. If you're looking for Ironwood Pharmaceuticals (IRWD) stock information, you might also want to check out Adamis Pharmaceuticals (NasdaqCM:ADMP).

$12.50

9.65% Upside

Hold
Hold

Ironwood Pharmaceuticals Fair Value Forecast for 2023 - 2025 - 2030

In the last two years, Ironwood Pharmaceuticals's Price has grown, increasing from $6.73 to $14.19 – an increase of 110.91%. According to 0 major analysts, Ironwood Pharmaceuticals's Fair Value will fall by 31.39% in the next year, reaching $9.73. Professionals believe that By 2030, Ironwood Pharmaceuticals's Fair Value will fall to $10.60– a 25.25% decrease from its current value.

2022 Fair Value Forecast
$9.73
2023 Fair Value Forecast
$9.20
2024 Fair Value Forecast
$9.80
2025 Fair Value Forecast
$11.28
2026 Fair Value Forecast
$10.78
2027 Fair Value Forecast
$10.25
2028 Fair Value Forecast
$10.14
2029 Fair Value Forecast
$10.51
2030 Fair Value Forecast
$10.60
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
AZN Stock Forecast AstraZeneca PLC Outperform 8
£10.58k £153.20 -98.53%
4502 Stock Forecast Takeda Pharmaceutical Company Outperform 16
¥4.08k ¥0.00 7.84%
PCRX Stock Forecast Pacira BioSciences Outperform 16
$41.86 $79.67 86.34%
SUPN Stock Forecast Supernus Pharmaceuticals Outperform 16
$41.61 $35.50 -18.29%
MNKP.F Stock Forecast Mallinckrodt - 12
$19.00 $1.50 9.11%

Ironwood Pharmaceuticals Revenue Forecast for 2023 - 2025 - 2030

In the last two years, Ironwood Pharmaceuticals's Revenue has seen a drop from $428.41M to $413.75M – a 3.42% decrease. According to 0 major analysts, Ironwood Pharmaceuticals's Revenue will fall by 0.58% in the next year, reaching $411.35M. Professionals believe that By 2030, Ironwood Pharmaceuticals's Revenue will fall to $410.89M– a 0.69% decrease from its current value.

2022 Rev Forecast
$0.41B
2023 Rev Forecast
$0.42B
2024 Rev Forecast
$0.41B
2025 Rev Forecast
$0.41B
2026 Rev Forecast
$0.41B
2027 Rev Forecast
$0.41B
2028 Rev Forecast
$0.41B
2029 Rev Forecast
$0.41B
2030 Rev Forecast
$0.41B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
NKTR Stock Forecast Nektar Therapeutics Hold 11
$3.09 $29.50 48.87%
COLL Stock Forecast Collegium Pharmaceutical Buy 11
$28.59 $27.50 1.43%
NasdaqGS:BDSI Stock Forecast BioDelivery Sciences Internati... - 11
$5.59 $10.00 78.89%

Ironwood Pharmaceuticals Dividend per Share Forecast for 2023 - 2025 - 2030

Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
ANIP Stock Forecast ANI Pharmaceuticals Outperform 13
$44.67 $61.67 0.74%
ASRT Stock Forecast Assertio Holdings Outperform 8
$4.10 $5.83 46.34%
RDHL Stock Forecast RedHill Biopharma Buy 0
$0.95 $0.00 847.37%

Ironwood Pharmaceuticals Free Cash Flow Forecast for 2023 - 2025 - 2030

In the last two years, Ironwood Pharmaceuticals's Free Cash Flow has grown by 38575.00%, from $-680.00k to $261.63M. In the following year, 0 experts forecast that Ironwood Pharmaceuticals's Free Cash Flow will decrease by 57.58%, to $110.97M. In 2030, professionals predict that Ironwood Pharmaceuticals's Free Cash Flow will decrease by 35.60%, to $168.50M.

2022 FCF Forecast
$0.11B
2023 FCF Forecast
$0.11B
2024 FCF Forecast
$0.15B
2025 FCF Forecast
$0.20B
2026 FCF Forecast
$0.17B
2027 FCF Forecast
$0.15B
2028 FCF Forecast
$0.15B
2029 FCF Forecast
$0.17B
2030 FCF Forecast
$0.17B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
ACRX Stock Forecast AcelRx Pharmaceuticals Outperform 6
$0.29 $4.25 1279.31%
AQST Stock Forecast Aquestive Therapeutics Outperform 0
$2.93 $0.00 241.30%
CPIX Stock Forecast Cumberland Pharmaceuticals - 0
$2.23 $0.00 10.76%

Ironwood Pharmaceuticals Net Income Forecast for 2023 - 2025 - 2030

In the last two years, Ironwood Pharmaceuticals's Net Income has grown, increasing from $21.51M to $528.45M – a growth of 2356.76%. According to 0 analysts, Ironwood Pharmaceuticals's Net Income will fall by 79.85% in the next year, reaching $106.47M. Professionals believe that By 2030, Ironwood Pharmaceuticals's Net Income will fall to $487.26M – a 7.79% decrease from its current value.

2022 NI Forecast
$0.11B
2023 NI Forecast
$0.19B
2024 NI Forecast
$0.36B
2025 NI Forecast
$0.73B
2026 NI Forecast
$0.39B
2027 NI Forecast
$0.38B
2028 NI Forecast
$0.43B
2029 NI Forecast
$0.54B
2030 NI Forecast
$0.49B

Ironwood Pharmaceuticals EBITDA Forecast for 2023 - 2025 - 2030

In the last two years, Ironwood Pharmaceuticals's EBITDA has grown from $129.05M to $234.04M – a 81.36% increase. 0 analysts predict Ironwood Pharmaceuticals's EBITDA will decrease by 27.38% in the next year, reaching $169.95M. By 2030, professionals predict that Ironwood Pharmaceuticals's EBITDA will decrease by 22.68%, to $180.95M.

2022 EBITDA Forecast
$0.17B
2023 EBITDA Forecast
$0.16B
2024 EBITDA Forecast
$0.17B
2025 EBITDA Forecast
$0.19B
2026 EBITDA Forecast
$0.18B
2027 EBITDA Forecast
$0.18B
2028 EBITDA Forecast
$0.17B
2029 EBITDA Forecast
$0.18B
2030 EBITDA Forecast
$0.18B

Ironwood Pharmaceuticals EBIT Forecast for 2023 - 2025 - 2030

In the last two years, Ironwood Pharmaceuticals's EBIT has grown by 88.32%, rising from $123.47M to $232.52M. For the following year, the 0 analysts predict that Ironwood Pharmaceuticals's EBIT will drop by 28.54%, reaching $166.17M. In 2030, the professionals' prediction is that IRWD's EBIT will decrease by 23.44%, reaching $178.01M.

2022 EBIT Forecast
$0.17B
2023 EBIT Forecast
$0.16B
2024 EBIT Forecast
$0.17B
2025 EBIT Forecast
$0.19B
2026 EBIT Forecast
$0.18B
2027 EBIT Forecast
$0.17B
2028 EBIT Forecast
$0.17B
2029 EBIT Forecast
$0.18B
2030 EBIT Forecast
$0.18B

Ironwood Pharmaceuticals EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last two years, Ironwood Pharmaceuticals's EPS has grown, increasing from $0.55 to $1.16 – an increase of 110.91%. According to 0 major analysts, Ironwood Pharmaceuticals's EPS will fall by 31.39% in the next year, reaching $0.80. Professionals believe that By 2030, Ironwood Pharmaceuticals's EPS will fall to $0.87– a 25.25% decrease from its current value.

2022 EPS Forecast
$0.80
2023 EPS Forecast
$0.75
2024 EPS Forecast
$0.80
2025 EPS Forecast
$0.92
2026 EPS Forecast
$0.88
2027 EPS Forecast
$0.84
2028 EPS Forecast
$0.83
2029 EPS Forecast
$0.86
2030 EPS Forecast
$0.87